Trial Profile
Prospective Assessment of Whether Adjuvant Netarsurdil Use Improves Post-Operative Outcomes in Patients Undergoing Descemetorhexis Without Endothelial Keratoplasty
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Netarsudil (Primary)
- Indications Fuchs' endothelial dystrophy
- Focus Therapeutic Use
- 11 Mar 2024 Status changed from active, no longer recruiting to completed.
- 17 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2022 Planned End Date changed from 1 Apr 2022 to 1 Dec 2023.